Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Bedaquiline: Current status and future perspectives

Fri Aug 19 03:13:32 2022

(2021) Bedaquiline: Current status and future perspectives. Journal of global antimicrobial resistance. pp. 48-59. ISSN 2213-7173 (Electronic) 2213-7165 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/33684606

Abstract

The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.

Item Type: Article
Creators:
CreatorsEmail
Khoshnood, S.UNSPECIFIED
Goudarzi, M.UNSPECIFIED
Taki, E.UNSPECIFIED
Darbandi, A.UNSPECIFIED
Kouhsari, E.UNSPECIFIED
Heidary, M.UNSPECIFIED
Motahar, M.UNSPECIFIED
Moradi, M.UNSPECIFIED
Bazyar, H.UNSPECIFIED
Keywords: Bedaquiline Multidrug resistance Mycobacterium tuberculosis Tuberculosis
Divisions:
Page Range: pp. 48-59
Journal or Publication Title: Journal of global antimicrobial resistance
Journal Index: Pubmed
Volume: 25
Identification Number: https://doi.org/10.1016/j.jgar.2021.02.017
ISSN: 2213-7173 (Electronic) 2213-7165 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/3378

Actions (login required)

View Item View Item